RCEL

#3281
Avita Medical, Inc. - Common Stock
10.1 9 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
10.12
10.29
Intervallo Annuale
3.22
10.77
Variazione giornaliera
-1.55%
Variazione Mensile
+126.44%
Variazione di 6 mesi
+107.11%
Variazione Annuale
+134.79%
Chiusura Precedente
10.3 5
Open
10.1 6
Minimo
10.1 2
Massimo
10.2 9
Volume
87
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
AVITA Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
AVITA Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
AVITA Medical, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
AVITA Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
AVITA Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
AVITA Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
AVITA Medical, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
AVITA Medical, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
AVITA Medical, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
AVITA Medical, Inc. current report, Q1 FY2026
8-K

AVITA Medical, Inc. current report, Q1 FY2025

Full document

AVITA Medical, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by AVITA Medical, Inc. (Nasdaq: RCEL) on March 17, 2025. The filing discloses the entry into material definitive agreements with Stedical Scientific, Inc. regarding the Company's flagship product, PermeaDerm Biosynthetic Wound Matrix.

Key Financial Metrics

The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The document focuses exclusively on the terms of new contractual agreements.

Material Changes and Agreements

  • Contract Manufacturing Agreement: AVITA Medical Americas, LLC entered into a 10-year agreement with Stedical Scientific to manufacture PermeaDerm in the United States. Production will support sales within the U.S. and supply Stedical Scientific for distribution outside the U.S.
  • Amendment to Distribution Agreement: The Company amended its exclusive distribution agreement with Stedical Scientific. Key changes include:
    • AVITA Medical's revenue share from PermeaDerm sales increased from 50% to 60%.
    • Stedical Scientific became eligible for milestone payments contingent on AVITA Medical achieving specified sales targets.
    • The initial term of the Distribution Agreement was revised to 10 years from the date of the amendment.

Outlook, Risks, and Management Commentary

Management announced these agreements via a press release on March 17, 2025. The agreements are intended to solidify the manufacturing and distribution framework for PermeaDerm. The filing does not contain specific forward-looking guidance, risk factors, or discussion of contingencies beyond the terms of the new contracts.

Investor Verification Checklist

  • Verify the specific sales targets required for Stedical Scientific to receive milestone payments.
  • Confirm the impact of the increased 60% revenue share on future gross margins.
  • Review the full text of the Manufacturing Agreement (Exhibit 10.1) for termination clauses or performance obligations.
  • Assess the operational capacity of the new U.S. manufacturing arrangement.

Notizie